
BNXTF
Healthcare · Drug Manufacturers - Specialty & Generic · $21.0M market cap
$0.15400.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2022
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 31, 2026 | Time not confirmed | — | -0.01 | — |
| May 29, 2026 | Time not confirmed | — | -0.02 | — |
| Nov 28, 2025 | Time not confirmed | — | -0.01 | — |
| Sep 1, 2025 | Time not confirmed | — | -0.01 | — |
| Jun 27, 2025 | Time not confirmed | — | -0.01 | — |
| Nov 29, 2024 | Time not confirmed | — | -0.01 | — |
| Aug 26, 2024 | Time not confirmed | — | -0.01 | — |
| May 29, 2024 | Time not confirmed | — | -0.01 | — |
| Dec 5, 2023 | Time not confirmed | — | -0.01 | — |
| Aug 30, 2023 | Time not confirmed | — | -0.02 | — |
| May 26, 2023 | Time not confirmed | — | -0.01 | — |
| Nov 28, 2022 | Time not confirmed | — | -0.02 | — |
| Aug 29, 2022 | Time not confirmed | — | -0.01 | — |
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for…
| After the close |
| -0.03 |
| -0.11 |
| -266.7% |
| Nov 26, 2021 | After the close | -0.06 | -0.04 | +33.3% |
| Aug 27, 2021 | After the close | — | -0.05 | — |
| May 5, 2021 | After the close | — | -0.07 | — |